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Role for transforming growth factor-b1 in Alport renal disease the covalent and noncovalent association of the carboxy-
progression. and amino-terminal globular domains of heterotrimeric
Background. Alport syndrome results from mutations in ei- protomer building blocks into a supramolecular com-ther the a3(IV), a4(IV), or a5(IV) collagen genes. The disease
plex. A variety of other proteins associate with the base-is characterized by a progressive glomerulonephritis usually asso-
ment membrane via noncovalent interactions, impartingciated with a high-frequency sensorineural hearing loss. A mouse
model for an autosomal form of Alport syndrome [collagen structurally and functionally unique characteristics to the
a3(IV) knockout] was produced and characterized. In this study, basement membrane. Type IV collagen is encoded by
the model was exploited to demonstrate a potential role for six different genes arranged in pairs in a head-to-headtransforming growth factor-b1 (TGF-b1) in Alport renal dis-
configuration at three different loci in the genome [1].ease pathogenesis.
Methods. Kidneys from normal and Alport mice, taken at The type IV collagen a1(IV) and a2(IV) chains are
different stages during the course of renal disease progression, found in all basement membranes, whereas the a3(IV),
were analyzed by Northern blot, in situ hybridization, and immu- a4(IV), a5(IV), and a6(IV) chains have a more limited
nohistology for expression of TGF-b1 and components of the
tissue distribution [2, 3]. The rules governing collagenextracellular matrix. Normal and Alport human kidney was
chain associations to form the superstructure have beenexamined for TGF-b1 expression using RNase protection.
Results. The mRNAs encoding TGF-b1 (in both mouse and partially worked out [4, 5]; however, there are still many
human), entactin, fibronectin, and the collagen a1(IV) and unanswered questions.
a2(IV) chains were significantly induced in total kidney as a In the renal glomerulus, the glomerular basementfunction of Alport renal disease progression. The induction of
membrane (GBM) is found between the endothelial andthese specific mRNAs was observed in the glomerular podo-
visceral epithelial (podocyte) cell layers. Filtration of thecytes of animals with advanced disease. Type IV collagen,
laminin-1, and fibronectin were markedly elevated in the tubu- blood occurs through gaps in the cellular architecture of
lointerstitium at 10 weeks, but not at 6 weeks, suggesting that the two cell types, with fenestrated endothelial cells lin-
elevated expression of specific mRNAs on Northern blots re-
ing the capillaries on one side of the GBM and the slitflects events associated with tubulointerstitial fibrosis.
diaphragm between the podocyte foot processes on theConclusions. The concomitant accumulation of mRNAs en-
coding TGF-b1 and extracellular matrix components in the other. The GBM in the adult mammal is comprised of
podocytes of diseased kidneys may reflect key events in Alport two different networks of type IV collagen [5, 6]. The
renal disease progression. These data suggest a role for TGF-b1
a1(IV) and a2(IV) chains are found along the subendo-in both glomerular and tubulointerstitial damage associated
thelial cell aspect of the GBM, whereas the a3(IV),with Alport syndrome.
a4(IV), and a5(IV) chains are found through its entire
width. At the time of birth in the mouse, the GBM
is comprised entirely of a1(IV) and a2(IV) chains. ByThe structural foundation of all basement membranes
is type IV collagen. This unique collagen is assembled by postnatal day four, however, the genes encoding the
a3(IV), a4(IV), and a5(IV) chains are activated, and
the adult collagen composition of the GBM becomesKey words: Alport syndrome, extracellular matrix, TGF-b, IDDM,
diabetes. apparent [7]. This developmentally regulated type IV
collagen isoform switching is also observed in both hu-Received for publication November 4, 1998
mans and dogs [8, 9].and in revised form May 20, 1999
Accepted for publication June 14, 1999 Alport familial nephritis is a progressive disease that
affects approximately 1 in 20,000 people [10, 11]. The 1999 by the International Society of Nephrology
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genetic lesions that result in the disorder are mutations approved protocol, and every effort was used to mini-
mize pain and distress.that inhibit the expression of either the a5(IV), which
is the more common X-linked form of Alport syndrome
Protein analysis[12], or the a4(IV) or a3(IV) genes, which account for
Analysis for urinary albumin was performed by poly-the autosomally inherited forms of the disease [13]. Re-
acrylamide gel electrophoresis (PAGE) and Coomassiegardless of which gene is mutated, the end result is the
blue staining as described previously [17].absence of all three chains in the mature GBM [14, 15],
although some exceptions have been noted [16]. Thus,
Northern analysisthe GBM in most patients with Alport syndrome is com-
Probes used for Northern analysis were as describedprised entirely of the a1(IV) and a2(IV) chains [14]. The
[17], except for the TGF-b1 probe, which was a gift fromresulting progressive glomerulonephritis may result from
H.L. Moses and was described previously [21]. Totalthis fundamental change in GBM collagen composition.
RNA was isolated from whole kidneys using TrizolThe molecular mechanism by which this primary differ-
(GIBCO/BRL, Grand Island, NY, USA) according toence precipitates the observed changes in GBM structure
the procedure described by the manufacturer. Twentyand composition is not yet clear. One view suggests that
micrograms were fractionated on formaldehyde gels,the Alport GBM is structurally unsound and falls apart
transferred by capillary blot to uncharged nylon, andunder the stress of normal glomerular function [14].
probed with 32P-labeled cDNA probe fragments. ProbesStudies have shown that GBM collagen comprised en-
were labeled to a specific activity greater than 109 disinte-tirely of the a1(IV) and a2(IV) chains is more susceptible
grations per minute (DPM)/mg of DNA using a randomto endoproteolysis in vitro [8]. Another view suggests
priming DNA labeling kit (Boeringer Mannheim, Mann-that changes in GBM composition may alter the homeo-
heim, Germany). Prehybridization and hybridization buff-stasis of GBM remodeling via changes in the interaction
ers consisted of 5 3 standard saline citrate (SSC), 5 3with cell adhesion molecules such as the integrins [17].
Denhardt’s solution, 0.5% sodium dodecyl sulfate (SDS),In an earlier report, this laboratory described the pro-
and 200 mg/ml sonicated and denatured salmon spermduction and initial characterization of a mouse model
DNA. Filters were prehybridized for at least five hoursfor an autosomal form of Alport syndrome produced via
and then hybridized overnight using one million DPM oftargeted mutagenesis using embryo-derived stem cells
probe per milliliter of hybridization solution. The filters[17]. Significant basement membrane ultrastructural ir-
were then washed at high stringency and exposed to x-rayregularities and accumulation of basement membrane-
film. The quality of the RNA preparations and the consis-associated proteins were observed prior to the onset of
tency of loading were assessed by staining gels with ethid-
proteinuria. The accumulation of these proteins followed
ium bromide and scanning the 18S and 28S ribosomal
course with progressive structural irregularities in the RNA bands using an Applied Imaging digital imaging
GBM, ultimately culminating in fibrosis. system (Gel Imager 2000, Applied Imaging, Inc., Santa
In efforts to understand better the mechanism by Clara, CA, USA) instrument and software package. Ap-
which these proteins accumulate, the corresponding propriate ratios of ribosomal bands confirmed that the
mRNAs were examined by Northern blot and in situ RNA preparations were of high and consistent quality.
hybridization analysis. In this report, we illustrate that Quantitative densitometric scanning confirmed no more
the mRNAs encoding some of these proteins are induced than a 10% variance in sample loading. These tools were
following the onset of proteinuria and that the induction used rather than a control probe because of concerns that
occurs primarily in the podocytes. The observed induc- changes in cell physiology concomitant with progressive
tion of transforming growth factor-b1 (TGF-b1) mRNA fibrosis makes such control probes unreliable. Quantita-
and protein (observed in both human and murine kid- tive differences in expression were assessed by phosphor-
neys) may be of particular importance, because earlier image analysis using a Bio-Rad GS-525 phosphorimager
studies using various experimental systems link overex- (Bio-Rad, Richmond, CA, USA) and background hy-
pression of TGF-b1 with the induction of genes encoding bridization was subtracted.
extracellular matrix proteins [18–20].
RNase protection
The RNase protection procedure was used to deter-METHODS
mine relative levels of TGF-b1 mRNA in normal versus
Mice Alport human kidneys. Because a small product is de-
Tissues were harvested from F2 backcrosses of 129 tected, this procedure is not as sensitive to a small degree
Sv/J founder animals onto the C57 Bl/6 background. All of RNA degradation as are Northern blots. Experiments
procedures using animals were conducted under an Insti- were carried out using a RPAII kit (Ambion, Inc., Aus-
tin, TX, USA) following the protocols provided with thetutional Animal Care and Use Committee (IACUC)–
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kit. For a probe, a 264-base pair fragment of TGF-b1 was and fibronectin immunoperoxidase staining, 3 mm paraf-
fin sections were digested with 0.025% pepsin in 10 mmamplified by polymerase chain reaction from a human
kidney cDNA library (Clonetech, Palo Alto, CA, USA). HCl for five minutes at 378C. All other procedures were
as for the TGF-b1 stains. Secondary antibodies wereThe primer sets used were GCA GAA GTT GGC ATG
GTA G (antisense) and GGA CAT CAA CGG GTT biotinylated anti-rabbit (for fibronectin and laminin-1)
and anti-goat (for type IV collagen). These reagents wereCAC TA (sense). The fragment was reamplified with
PFU polymerase (Stratagene, La Jolla, CA, USA) and purchased from Vector Laboratories and were used at
a 1:100 dilution.blunt-end ligated into the pBluescript SK1 plasmid
(Stratagene). The antisense probe was generated from
In situ hybridizationthe T7 promoter. Alport kidney RNA was isolated from
a small piece of renal cortex taken from a 10-year-old Kidneys were initially fixed by slow transcardiac perfu-
sion (using 4% paraformaldehyde in PBS). The animalsboy following renal transplant. The kidney was near end
stage. A small specimen of the dissected cortex was ana- were first deeply anesthetized using Avertin (2,2,2-tri-
bromoethanol). The chest cavity was opened, and a smalllyzed using standard histochemical techniques and was
found to be moderately scarified; however, approxi- hole was made in the right ventricle by puncturing with
a tuburculin needle to allow the exit of the perfusate. Amately half of the tubules and glomeruli appeared func-
tional. Kidney RNA for normal controls was purchased second tuberculin needle connected to a 30 ml syringe
containing PBS was inserted into the apex of the leftfrom Clonetech, Inc. The integrity of the RNA used in
the experiments was checked by gel electrophoresis and ventricle. One milliliter of PBS was perfused per gram
body weight at a rate of approximately 3 ml/min. Thewas found to be intact and similar for the two samples.
process was then repeated using ice-cold 4% paraformal-
Immunohistochemical analysis dehyde in PBS as fixative. Properly fixed kidneys were
firm and had a pale appearance. Following perfusion,Tissue was embedded in paraffin and sectioned at 5 mm.
Deparaffinized sections were pretreated with 5 mg of the renal capsule was removed with iris forceps. Kidneys
were cut in half longitudinally (bisecting the pelvis, me-proteinase K in 100 mm Tris-HCl (pH 7.4) to expose
epitopes. The proteinase digestion was stopped by incu- dulla, and cortex) and placed in fixative at 48C for an
additional hour. The fixed halves were embedded in par-bating in 2 mg/ml glycine in phosphate-buffered saline
(PBS) for 30 seconds. The primary antibody was either affin, cut at 6 mm, and transferred onto superfrost plus
(Fisher Scientific, Inc., Pittsburgh, PA, US) microscopechicken antihuman TGF-b1 or goat antihuman TGF-b1
LAP (R&D Systems, Minneapolis, MN, USA) used at slides. Slides were baked on a slide warmer at 608C for
20 minutes and stored at 48C until used (slides are usefula 1:15 dilution in 7% nonfat dry milk in PBS (which was
used as diluent for all antibodies). This was allowed for up to six weeks). Kidneys from control and Alport
littermates were embedded side by side to control forto react for at least three hours at room temperature.
Following three washes in PBS, the secondary antibody, subtle differences that might be incurred during the hy-
bridization procedure.which was a biotinylated goat anti-chicken (for TGF-b1)
or rabbit anti-goat (for TGF-b1 LAP; both purchased Slides were baked in a vacuum oven at 608C for one
hour and then dewaxed by three successive two-minutefrom Vector Laboratories, Burlingame, CA, USA) was
applied at a 1:100 dilution and allowed to react for at least washes in xylenes. The tissue was dehydrated in ethanol,
deproteinated by incubating in 0.2 N HCl for 15 minutes,one hour. Following three washes, immunoperoxidase
detection was performed using the AEC kit from Vector washed, and digested with 3 mg/ml proteinase K (Boeh-
ringer Mannheim) for 10 minutes at 378C. The digestionLaboratories.
Immunoperoxidase staining for type IV collagen, lami- was stopped by washing in 2 mg/ml glycine in PBS. Fol-
lowing dehydration of the tissue in graded ethanol solu-nin-1, and fibronectin was performed as described pre-
viously [17]. Goat antisera against human placentally tions, the tissue was prehybridized, hybridized, and
washed according to the protocols described with thederived collagen a1(IV) and a2(IV) chains was purchased
from Southern Biotechnology (Birmingham, AL, USA). Genius in situ hybridization kit (Boehringer Mannheim)
with the following modifications: In both prehybridiza-Laminin-1 specific antisera was against EHS laminin and
was purchased from Sigma Immunochemicals (St. Louis, tion and hybridization solutions, 10 mg/ml phenol/chlo-
roform-extracted bakers yeast tRNA were included. ThisMO, USA). Antifibronectin antibodies were raised using
human plasma fibronectin as immunogen and purchased step significantly reduced nonspecific signal. Following
the hybridization, the tissue was washed twice in 2 3from Sigma Immunochemicals. All of these commer-
cially available antibody preparations have been exten- SSC at 508C and then digested with RNase A for six
minutes at room temperature. The amount of RNase Asively tested for cross-reactivity with other basement
membrane proteins and have been proved to be specific is critical and has to be determined for each probe (range
from 200 ng/ml to 5 mg/ml). Negative control probesfor their intended target. For type IV collagen, laminin-1,
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6 weeks and ending at 12 weeks of age. The RNA was
fractionated on denaturing agarose gels, transferred to
nylon supports, and probed with radiolabeled probes
specific for either the a1(IV) or a2(IV) collagen chains,
entactin, the laminin b1 or b2 chains, fibronectin, or
TGF-b1. The results in Figure 2 illustrate that the
mRNAs for all of these proteins with the exception of
laminin b1 and b2 are induced following the onset of
proteinuria in the Alport mouse model. Northern blots
for this same time course were also performed for lami-
nin a1, laminin g1, heparan sulfate proteoglycan core
protein, and the collagen a4(IV), and a5(IV) chains
(data not shown). No significant differences in mRNA
levels for these other basement membrane proteins were
apparent when comparing the control to the mutant.
Fig. 1. Analysis of urinary albumin as a function of renal disease pro- The results of the Northern analyses were analyzed
gression in the Alport mouse. Urine was collected from animals prior
using a phosphorimager to directly quantitate the rela-to the harvest of kidneys for RNA isolation and immunohistochemical
analysis. One microliter (equivalent) of urine from each time point was tive changes in specific mRNA expression during the
fractionated on SDS-acrylamide gels and stained with Coomassie blue. time course. Figure 3 illustrates that induction of the
specific mRNA levels is apparent at six weeks of age or
about the time when protein in the urinary space reaches
the maximum levels in the F2 mice [17]. By eight weeks,include the coding sequence for bacterial b-galactosidase
mRNA levels peak, with the mRNAs encoding TGF-b1or neomycin phosphotransferase. All probes were ap-
and fibronectin induced 6.6- and 9.4-fold over that ofproximately 200 bases in length, cloned into the SacI site
control mice, respectively. The mRNA levels for colla-of BlueScript SK1 (Stratagene, Inc.), and transcribed
gen a1(IV), a2(IV), and entactin were all about threefold(after linearization) from the T3 side. Transcription was
induced by week 8. In contrast, no significant changescarried out using T3 polymerase and the digoxigenin
in mRNAs encoding the laminin b1 and b2 chains, asNTP substrates provided in the Genius in situ hybridiza-
determined by these same total RNA northern blots,tion kit. The only exception was TGF-b1, which was 974
were observed at any point in renal disease progression.bases and cloned into a pmT vector. Detection of signal
The Northern blot data shown in Figures 2 and 3was performed using the components and procedures
are likely representative of what is happening in theprovided in the Boehringer Mannheim Genius kit. The
tubulointerstitium, because the RNA was isolated fromChromagenic reaction was monitored visually using an
whole kidney, and the renal tubules comprise the major-inverted microscope and was allowed to develop until
ity of the total mass. The tubulointerstitium was thusthe specific signal was easily interpreted (not overdevel-
examined using immunoperoxidase immunodetectionoped), but before significant background staining (that
techniques with antibodies directed against either colla-for the b-galactosidase probe) was observed. Invariably,
gen a1(IV) and a2(IV) chains, laminin-1, or fibronectin.the signal in the tubules developed significantly faster
Kidneys were harvested when the animals were eitherthan that in the glomeruli.
6 or 10 weeks of age. The results in Figure 4 illustrate thatExperiments were performed at least twice (on speci-
immunostaining in the tubulointerstitium at six weeks ismens from 2 different sets of animals). Results for data
very similar in Alport mice compared with normal micepresented herein were clear and consistent.
for all three matrix proteins. By 10 weeks of age, how-
ever, there is a marked increase in collagen a1(IV) and
RESULTS a2(IV) (Fig. 5 B vs. A) and fibronectin (Fig. 5 F vs. E),
with a lesser increase in laminin-1 (Fig. 5 D vs. C) inProteinuria in the F2 mice used in this study begins
when the mice are approximately 5.5 to 6 weeks of age. the tubulointerstitium of mutant mice relative to that in
controls. These results are consistent with observationsFigure 1 illustrates PAGE fractionated urine protein col-
lected at weekly intervals during the time course. The made by Northern blot analysis (Fig. 2).
The glomeruli comprise only a small percentage ofsix- and eight-week samples were taken just prior to
harvest of the kidneys for RNA isolation. It is clear from the total mass of the kidney. Individual cell types within
the glomeruli comprise an even lesser percentage. North-this gel that proteinuria is low in the six-week-old mice
but reaches maximum levels by eight weeks of age. Total ern blots of total kidney RNA are therefore not likely
to detect induction of messages that might be specific toRNA was isolated from whole kidneys of Alport animals
and control littermates at two-week intervals starting at glomeruli or to a particular glomerular cell type. To
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Fig. 2. Northern analysis of mRNAs from total kidney during a time course of Alport renal disease progression. Total RNA isolated from kidneys
harvested at the indicated time points (in weeks) was fractionated on denaturing agarose gels, blotted onto nylon, and probed with murine cDNAs
encoding either TGF-b1 or various components of the glomerular basement membrane and/or the extracellular matrix. The specificity of the
probes used are indicated below each panel.
examine whether the mRNAs encoding TGF-b1 or the this molecule localizes in the mature animal [22]. In
the mutant, expression in the mesangial matrix may bedifferent basement membrane components were induced
in a particular glomerular cell type, in situ hybridization elevated, as evidenced by much darker staining when
compared with the mesangial cell staining in the controlwas performed using digoxygenin-labeled antisense
probes specific for the mRNAs. A riboprobe produced sample; however, the most obvious difference between
the control and the mutant is the ring of stained cellsfrom the bacterial b-galactosidase gene was used as a
negative control, as this probe did not hybridize to total lining the outer circumference of the glomerulus, corre-
sponding to the podocytes (Fig. 6B). Fibronectin expres-mouse kidney RNA on Northern blots or RNA dot blots
(data not shown). The probes were hybridized to paraffin sion in the control glomerulus is very weak (Fig. 6G),
whereas in the mutant, the podocytes are clearly express-sections of kidneys harvested at 10 weeks of age from
control and COL4A3-deficient mice. This time point was ing significant levels of fibronectin mRNA (Fig. 6H). The
expression of TGF-b1 is very weak in the glomeruli ofchosen because the mRNAs are clearly induced (Fig. 2),
but the majority of the glomeruli are not yet fibrotic. the control animals; however, some specific staining is
observed in the mesangial cells (Fig. 6D). In the mutant,The results in Figure 6 illustrate that for all specific
mRNAs examined, elevated levels are clearly observed TGF-b1 mRNA levels are, again, significantly elevated
in the podocytes (Fig. 6E). For entactin, the mRNAin the podocytes of the glomerulus in the COL4A3
knockout mice. For the collagen a1(IV) chain, the ex- localized to the podocytes of the control, which is not
unexpected as this protein localizes specifically to thepression of the mRNA in the control is observed in
both the mesangial cells and the endothelial cells of the GBM [22]. Unexpectedly, some mesangial cell-specific
staining is observed in the control animal. Although theglomerulus (Fig. 6A), which is consistent with where
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munostaining patterns for the active cytokine in glomer-
uli from control versus mutant animals mirror the pattern
of mRNA expression observed by in situ hybridization
(compare Fig. 6D with Fig. 7A, and Fig. 6E with Fig.
7B). In the renal tubules, there were no discernible dif-
ferences in TGF-b1 immunostaining for Alport versus
control mice (Fig. 7 C, D).
The relevance of studies described herein depend on
the assumption that the gene knockout mouse model is
consistent with human Alport renal disease pathogene-
sis. To test this assumption, total RNA from normal
and Alport human renal cortex was subjected to RNase
protection analysis for TGF-b1 mRNA expression. The
results shown in Figure 8 illustrate that there is indeed
an elevation of the TGF-b1 message in human Alport
renal cortex relative to that from normal tissue. Phos-
phorimage analysis of the bands in Figure 8 found the
TGF-b1 mRNA threefold elevated in the Alport versus
the control samples.
DISCUSSIONFig. 3. Quantitative analysis of mRNA induction during Alport renal
disease progression. Following exposure to x-ray film, the membranes Renal disease pathogenesis in the Alport mouse model
used to produce Figure 1 were analyzed using a BioRad GS-525 phos-
seems to follow a two-step process that is divided by thephorimager. Plotted values indicate the fold induction of the specific
mRNA in the Alport sample over those observed in the normal lit- onset of proteinuria. Prior to the onset of proteinuria,
termate. All bands were subtracted against the background. The specific the fundamental difference in the Alport glomerulus is
mRNA species analyzed are: (d) TGF-b1; (.) Col4A1; (*) Col4A2;
the absence of the collagen a3,(IV), a4(IV), and a5(IV)(r) fibronectin; (j) entactin; (m) Lam-b1; (#) Lam-b2.
chains in the GBM. By four weeks of age (nearly 2 weeks
before the onset of proteinuria), there are significant base-
ment membrane changes, with focal thinning, thickening,
staining in the podocytes in the mutant seems to indicate and splitting. Also evident is a marked accumulation of
elevated expression, this is not a quantitative assay, and extracellular matrix components in the GBM of affected
the difference between the control and the mutant is too animals [17]. In this study, we examined the expression
small to be definitive (compare Fig. 6 J with K).
mRNAs encoding proteins known to accumulate in the
Northern blots revealed that mRNA levels for the
GBM of the Alport mouse model. Prior to the onset oflaminin b1 chain were unchanged in the control versus
proteinuria, we see no quantitative change in these specificthe mutant throughout the time course. In situ hybridiza-
mRNAs relative to that in control littermates by bothtion analysis for laminin b1 did not produce a visible
Northern analysis and in situ hybridization (data notsignal in glomeruli from control kidneys (Fig. 6M). In
shown). Following the onset of proteinuria, messagesthe glomeruli from mutant mice, however, the mRNA
encoding entactin, fibronectin, and the collagen a1(IV)is clearly induced in the podocytes (Fig. 6N).
and a2(IV) chains are induced threefold to ninefold.Tissue samples were harvested at three and five weeks
TGF-b1 mRNA follows the same time course for induc-of age and were analyzed by in situ hybridization using
tion, peaking at levels sixfold greater than those for nor-these same probes. The staining pattern in these glomer-
mal littermates. All of these mRNAs were significantlyuli were indistinguishable from those of normal litter-
elevated in the podocytes, suggesting that a change inmates (data not shown).
gene expression in these cells results in elevated synthesisThe presence of TGF-b1 mRNA in the podocytes does
and deposition of ECM in the GBM of the mutant ani-not distinguish the active form of the cytokine. To resolve
mals. Elevated levels of specific matrix RNAs, as mea-this issue, immunoperoxidase staining was performed
sured by Northern blot analysis, correlate well with accu-using an antibody preparation that is known to bind only
mulation of the matrix proteins in the tubulointerstitium,to the biologically active form of TGF-b1. As illustrated
suggesting that the induction of the mRNAs encodingin Figure 7, although in controls there appears to be
TGF-b1 and matrix proteins in total kidney reflect eventslittle if any active TGF-b1 in the podocytes (Fig. 7A,
associated with tubulointerstitial fibrosis. In contrastarrow), the cytokine is clearly evident in the podocytes
of the mutant animals (Fig. 7B, arrow). Indeed, the im- with that in the glomerulus, there was no change in the
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Fig. 4. Immunohistochemical detection of matrix proteins in the tubulointerstitium of normal versus Alport mice at six weeks of age. Kidneys
from normal (A, C, and E ) and Alport (B, D, and F ) mice were harvested at six weeks of age and embedded in paraffin. Sections were
immunostained using antibodies specific for either type IV collagen a1(IV) and a2(IV) chains (A and B), laminin-1 (B and C), or fibronectin (C
and D). Magnification is 350.
cellular distribution of TGF-b1 protein expression in the mouse model for insulin-dependent diabetes mellitus
(IDDM) glomerulonephritis [18, 23]. In the former, ei-tubules (Fig. 7 C, D).
This is the first report, to our knowledge, illustrating ther neutralizing antibodies against TGF-b1 [19] or anti-
sense oligonucleotides for the mRNA encoding TGF-b1a potential role for TGF-b1 in Alport renal disease pro-
gression. Induction of this cytokine has, however, been [24] were shown to be capable of suppressing the accu-
mulation of extracellular matrix, as well as the progres-implicated in progression of glomerulonephritis in ani-
mal models for both acute mesangial proliferative glo- sion of the renal disease. More recently, TGF-b1 has
been implicated to play a key role in IDDM glomerulo-merulonephritis and in the nonobese diabetic (NOD)
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Fig. 5. Immunohistochemical detection of matrix proteins in the tubulointerstitium of normal versus Alport mice at 10 weeks of age. Kidneys
from normal (A, C, and E ) and Alport (B, D, and F ) mice were harvested at six weeks of age and embedded in paraffin. Sections were
immunostained using antibodies specific for either type IV collagen a1(IV) and a2(IV) chains (A and B), laminin-1 (B and C), or fibronectin (C
and D). Magnification is 350.
nephritis using the streptozotocin-induced rat model protein levels) in cultured human glomerular epithelial
cells [27].[25]. A related study suggested that induction of TGF-b1,
fibronectin, and a1(IV) collagen is mediated via activity Transforming growth factor-b1 has also been shown
to induce genes encoding extracellular matrix proteins inof the b1 isoform of protein kinase C [26]. The primary
cause of IDDM glomerulonephritis is related to sus- cell culture using glomerular epithelial cells [20], murine
kidney proximal tubular cells [28], and smooth muscletained high glucose levels in poorly managed disease.
High glucose has been shown to induce expression of cells [29]. The genes found modulated by TGF-b1 in
these studies include those encoding the type IV colla-both TGF-b1 and fibronectin (at both the mRNA and
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Fig. 6. In situ hybridization analysis of specific transcripts in post-proteinuric Alport mice. Kidneys from 10 week mice were sectioned and
subjected to in situ hybridization analysis. Kidneys from normal littermates (A, D, G, and J ) were analyzed along side those from Alport mice
(B, E, H, and K). Antisense probes were specific for the NC1 domain of collagen a1(IV) (A and B), TGF-b1 (D and E), fibronectin (G and H),
entactin (J and K), or the laminin b1 chain (M and N ). A probe specific for bacterial b-galactosidase was used as a control for nonspecific binding
(C, F, I, L and O). The control probe was hybridized at the same time as each specific probe and treated with the same concentration of RNase
A following the hybridization procedure. RNase A treatment was carried out at 0.25 mg/ml for a1(IV), TGF-b1, and fibronectin, and at 3 mg/ml
for entactin and laminin b1.
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Fig. 7. Immunoperoxidase staining for TGF-b1 in tissue sections from normal and Alport mice. Paraffin-embedded sections from 10-week-old
control (A and C) or Alport (B and D) mice were stained for the active form of TGF-b1 using the immunoperoxidase method as described in
the methods section. Staining was developed using an AEC kit (Vector Laboratories). Fields provided illustrate immunostaining in the glomeruli
(A and B) or the tubules (C and D). Arrows denote podocytes; asterisks denote mesangial cells.
gens a1(IV) and a2(IV) chains and fibronectin, all genes
found in our studies to be induced as a function of Alport
renal disease progression. Experiments using transient
expression in murine proximal tubular cells illustrate that
that induction of the a1(IV) collagen gene by TGF-b1
is mediated by cis-elements in the bidirectional promoter
of the a1(IV)/a2(IV) gene cluster [28].
Whether protein in the urinary space causes the changes
in gene expression reported here is unclear. It is evident
from the clinical studies of Alport patients that persistent
massive proteinuria (exceeding 40 mg/hr/m2) indicates a
very poor prognosis [30, 31]. Although persistent mild
proteinuria may be tolerated without compromising glo-
merular function, massive proteinuria, if persistent, usu-
ally signifies pending glomerulonephritis [32]. It would
be of interest to determine whether protein in the urinary
Fig. 8. RNase detection analysis for TGF-b1 mRNA in normal and space can be directly linked to the induction of TGF-b1
Alport human renal cortex. Total RNA was isolated from normal and
or whether it is merely an indirect consequence.Alport human renal cortex, and 10 mg of each were subjected to RNase
protection analysis using a radiolabeled portion of the human TGF-b1 If elevated TGF-b1 expression is linked to the ob-
antisense message as a probe. The assay results in a 264 bp protected served induction of extracellular matrix genes in the
fragment. Molecular size markers are radiolabeled MSP1 cut PBR322,
mouse model, it may be acting through direct and/orand appropriate fragments are denoted for comparison. Abbreviations
are: N, normal; A, Alport. indirect mechanisms. Directly, it could bind receptors
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on the surface of the glomerular cell types and transduce the autosomal Alport mouse model may be shared by a
signals that lead to the induction of responsive genes. variety of progressive glomerulonephritises.
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